398 related articles for article (PubMed ID: 23792176)
1. Dysferlin interacts with calsequestrin-1, myomesin-2 and dynein in human skeletal muscle.
Flix B; de la Torre C; Castillo J; Casal C; Illa I; Gallardo E
Int J Biochem Cell Biol; 2013 Aug; 45(8):1927-38. PubMed ID: 23792176
[TBL] [Abstract][Full Text] [Related]
2. Dysferlin, annexin A1, and mitsugumin 53 are upregulated in muscular dystrophy and localize to longitudinal tubules of the T-system with stretch.
Waddell LB; Lemckert FA; Zheng XF; Tran J; Evesson FJ; Hawkes JM; Lek A; Street NE; Lin P; Clarke NF; Landstrom AP; Ackerman MJ; Weisleder N; Ma J; North KN; Cooper ST
J Neuropathol Exp Neurol; 2011 Apr; 70(4):302-13. PubMed ID: 21412170
[TBL] [Abstract][Full Text] [Related]
3. Intracellular localization of dysferlin and its association with the dihydropyridine receptor.
Ampong BN; Imamura M; Matsumiya T; Yoshida M; Takeda S
Acta Myol; 2005 Oct; 24(2):134-44. PubMed ID: 16550931
[TBL] [Abstract][Full Text] [Related]
4. AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration.
Huang Y; Laval SH; van Remoortere A; Baudier J; Benaud C; Anderson LV; Straub V; Deelder A; Frants RR; den Dunnen JT; Bushby K; van der Maarel SM
FASEB J; 2007 Mar; 21(3):732-42. PubMed ID: 17185750
[TBL] [Abstract][Full Text] [Related]
5. Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin.
Cai C; Weisleder N; Ko JK; Komazaki S; Sunada Y; Nishi M; Takeshima H; Ma J
J Biol Chem; 2009 Jun; 284(23):15894-902. PubMed ID: 19380584
[TBL] [Abstract][Full Text] [Related]
6. Dysferlin protein analysis in limb-girdle muscular dystrophies.
Vainzof M; Anderson LV; McNally EM; Davis DB; Faulkner G; Valle G; Moreira ES; Pavanello RC; Passos-Bueno MR; Zatz M
J Mol Neurosci; 2001 Aug; 17(1):71-80. PubMed ID: 11665864
[TBL] [Abstract][Full Text] [Related]
7. The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle.
Matsuda C; Hayashi YK; Ogawa M; Aoki M; Murayama K; Nishino I; Nonaka I; Arahata K; Brown RH
Hum Mol Genet; 2001 Aug; 10(17):1761-6. PubMed ID: 11532985
[TBL] [Abstract][Full Text] [Related]
8. Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B.
Gushchina LV; Bhattacharya S; McElhanon KE; Choi JH; Manring H; Beck EX; Alloush J; Weisleder N
Mol Ther; 2017 Oct; 25(10):2360-2371. PubMed ID: 28750735
[TBL] [Abstract][Full Text] [Related]
9. Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy.
Millay DP; Maillet M; Roche JA; Sargent MA; McNally EM; Bloch RJ; Molkentin JD
Am J Pathol; 2009 Nov; 175(5):1817-23. PubMed ID: 19834057
[TBL] [Abstract][Full Text] [Related]
10. Dysferlin in a hyperCKaemic patient with caveolin 3 mutation and in C2C12 cells after p38 MAP kinase inhibition.
Capanni C; Sabatelli P; Mattioli E; Ognibene A; Columbaro M; Lattanzi G; Merlini L; Minetti C; Maraldi NM; Squarzoni S
Exp Mol Med; 2003 Dec; 35(6):538-44. PubMed ID: 14749532
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry of sarcolemmal membrane-associated proteins in formalin-fixed and paraffin-embedded skeletal muscle tissue: a promising tool for the diagnostic evaluation of common muscular dystrophies.
Suriyonplengsaeng C; Dejthevaporn C; Khongkhatithum C; Sanpapant S; Tubthong N; Pinpradap K; Srinark N; Waisayarat J
Diagn Pathol; 2017 Feb; 12(1):19. PubMed ID: 28219397
[TBL] [Abstract][Full Text] [Related]
12. Variable reduction of caveolin-3 in patients with LGMD2B/MM.
Walter MC; Braun C; Vorgerd M; Poppe M; Thirion C; Schmidt C; Schreiber H; Knirsch UI; Brummer D; Müller-Felber W; Pongratz D; Müller-Höcker J; Huebner A; Lochmüller H
J Neurol; 2003 Dec; 250(12):1431-8. PubMed ID: 14673575
[TBL] [Abstract][Full Text] [Related]
13. Defective membrane repair in dysferlin-deficient muscular dystrophy.
Bansal D; Miyake K; Vogel SS; Groh S; Chen CC; Williamson R; McNeil PL; Campbell KP
Nature; 2003 May; 423(6936):168-72. PubMed ID: 12736685
[TBL] [Abstract][Full Text] [Related]
14. Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing.
Lennon NJ; Kho A; Bacskai BJ; Perlmutter SL; Hyman BT; Brown RH
J Biol Chem; 2003 Dec; 278(50):50466-73. PubMed ID: 14506282
[TBL] [Abstract][Full Text] [Related]
15. Calpain 3 is a modulator of the dysferlin protein complex in skeletal muscle.
Huang Y; de Morrée A; van Remoortere A; Bushby K; Frants RR; den Dunnen JT; van der Maarel SM
Hum Mol Genet; 2008 Jun; 17(12):1855-66. PubMed ID: 18334579
[TBL] [Abstract][Full Text] [Related]
16. Painful enlargement of the calf muscles in limb girdle muscular dystrophy type 2B (LGMD2B) with a novel compound heterozygous mutation in DYSF.
Diers A; Carl M; Stoltenburg-Didinger G; Vorgerd M; Spuler S
Neuromuscul Disord; 2007 Feb; 17(2):157-62. PubMed ID: 17129727
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro dysferlin expression in human muscle satellite cells.
De Luna N; Gallardo E; Illa I
J Neuropathol Exp Neurol; 2004 Oct; 63(10):1104-13. PubMed ID: 15535137
[TBL] [Abstract][Full Text] [Related]
18. Dysferlin interacts with affixin (beta-parvin) at the sarcolemma.
Matsuda C; Kameyama K; Tagawa K; Ogawa M; Suzuki A; Yamaji S; Okamoto H; Nishino I; Hayashi YK
J Neuropathol Exp Neurol; 2005 Apr; 64(4):334-40. PubMed ID: 15835269
[TBL] [Abstract][Full Text] [Related]
19. Case report of an adolescent girl with limb-girdle muscular dystrophy type 2B - the usefulness of muscle protein immunostaining in the diagnosis of dysferlinopathies.
Szymanska S; Rokicki D; Karkucinska-Wieckowska A; Szymanska-Debinska T; Ciara E; Ploski R; Grajkowska W; Pronicki M
Folia Neuropathol; 2014; 52(4):452-6. PubMed ID: 25574751
[TBL] [Abstract][Full Text] [Related]
20. Increased dysferlin expression in Duchenne muscular dystrophy.
Vontzalidis A; Terzis G; Manta P
Anal Quant Cytopathol Histpathol; 2014 Feb; 36(1):15-22. PubMed ID: 24902367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
